1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6188B47B8D58FD06D00258601001D3300
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/188B47B8D58FD06D00258601001D3300?OpenDocument
18
19OpenDocument
2035.170.64.36
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Digital Technology Investment Benchmarks

Best Practices in the Use of Digital Technologies within Medical Affairs: Roles, Reporting and Resourcing of Digital Initiatives in Medical Affairs

ID: 5646


Features:

10 Info Graphics

16 Data Graphics

260+ Metrics


Pages/Slides: 35


Published: 2020


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Best Practices in the use of Digital Technologies within Medical Affairs: Roles, Reporting and Resourcing of Digital Initiatives in Medical Affairs”

STUDY OVERVIEW

As biopharma organizations are increasingly turning to digital tools to shape Medical Affairs’ interactions with key stakeholders, they also need to adjust internally for roles, reporting, and resourcing.

Best Practices, LLC conducted this benchmarking research to probe the use of digital technologies within Medical Affairs. The study provides benchmarks around the roles, reporting and resourcing of digital initiatives in Medical Affairs.

Insights in this study are further presented into three different segments: Digital Leaders; Digital Majority; and Digital Laggards.

KEY TOPICS

  • Digital Initiative in Medical Affairs
  • Roles and Reporting in Digital Medical Affairs
  • Resourcing of Digital Initiatives

KEY METRICS
  • Which of the listed Medical Affairs sub-functions are involved with digital initiatives of any type at your organization and what role do they play?
  • What is the role of each of the listed Medical Affairs group(s) in driving digital initiatives?
  • What internal groups does Medical Affairs collaborate with to develop and support digital systems and engagement programs?
  • Approximately how much does your organization allocate for all Medical Affairs-related digital programs annually?
  • Approximately what percentage of your total Medical Affairs budget is allocated to digital initiatives currently?

SAMPLE KEY FINDINGS
  • Medical Affairs typically collaborates with other internal functions on digital efforts: When it comes to collaborating with internal groups to develop and support digital systems and engagement programs, Medical Affairs groups typically collaborate with IT (91%), Legal (85%), Compliance (83%), Regulatory (57%) and Commercial (53%) groups.

METHODOLOGY

Best Practices, LLC engaged 74 executives from 53 leading life sciences companies in this research through a benchmarking survey instrument and interviews. The study insights are mostly from directors and higher management executives, representing nearly 80% of the participants. Insights in this research are presented into three different segments to provide deeper insights: Digital Leaders (16 respondents); Digital Majority (38 respondents); and Digital Laggards (20 respondents).


Industries Profiled:
Biotech; Medical Device; Pharmaceutical; Biopharmaceutical; Diagnostic; Health Care; Chemical; Manufacturing; Communications; Clinical Research; Laboratories; Science; Consulting


Companies Profiled:
Aeglea BioTherapeutics; Alcon; Alexion Pharmaceuticals; Alkermes; Alnylam Pharmaceuticals; Astellas; AstraZeneca; BioDelivery Sciences International; Inc.; Biodesix; bioMerieux; Boehringer Ingelheim; Eisai; Eli Lilly and Company; EMD Serono; Exelixis ; GE Healthcare; Genentech; GRAIL; Grifols; GlaxoSmithKline ; Ipsen; Janssen; Jazz Pharmaceuticals; Julphar; Kedrion Biopharma; Lexicon Pharmaceuticals; Lundbeck; Mallinckrodt; Merck; MyoKardia; Nabriva Therapeutics; NexGen Healthcare Communications; Novartis; Novo Nordisk; Pfizer; Radius Health; Reata Pharmaceuticals; Roche; Sage Therapeutics; Sandoz; Sanofi; Sanofi Genzyme; Santen; Springworks Therapeutics; Sunovion; Takeda Pharmaceuticals; Terumo Corporation; Teva Pharmaceutical Industries Ltd; TG Therapeutics; Thermo Fisher Scientific; UCB Pharma; Vertex Pharmaceuticals; Vynamic

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.